1.	Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Phase: Phase III Type: Supportive care Status: Closed Age: 16 and over Sponsor: NCI, Other Protocol IDs: CDR0000068592, FHCRC-1577.00, MSKCC-01127, NCI-H01-0072, NCT00016068
2.	Phase II Pilot Study of Targeted Oncolytic Virotherapy Comprising Bortezomib, Zidovudine, and Valganciclovir Followed By Effusion Drainage and Bevacizumab in Combination With Chemotherapy Comprising Cyclophosphamide, Doxorubicin, and Etoposide in Patients With Primary Effusion Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-05-C-0203, NCI-P6330, NCT00217503
3.	Phase II Study of Phenylbutyrate and Valganciclovir in Patients With Relapsed or Refractory, Epstein-Barr Virus-Positive Malignancies Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCSD-050126, ROCHE-VAL-108, NCT00387530
4.	Pilot Study of Valganciclovir in Patients With Classic Non-HIV-Associated Kaposi's Sarcoma Phase: No phase specified Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-04055, NCT00096538
5.	Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection Phase: No phase specified Type: Supportive care Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: MV20145, Eudra CT: 2006-002022-29, NCT00400322